Beta Bionics Inc
NASDAQ:BBNX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Beta Bionics Inc
Change in Working Capital
Beta Bionics Inc
Change in Working Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Change in Working Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Beta Bionics Inc
NASDAQ:BBNX
|
Change in Working Capital
-$9m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Change in Working Capital
-$246m
|
CAGR 3-Years
37%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Change in Working Capital
$154.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
30%
|
CAGR 10-Years
9%
|
|
|
Stryker Corp
NYSE:SYK
|
Change in Working Capital
-$373m
|
CAGR 3-Years
33%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-8%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Change in Working Capital
-$803m
|
CAGR 3-Years
14%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
6%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Change in Working Capital
-$1.3B
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
-30%
|
|
Beta Bionics Inc
Glance View
Beta Bionics, Inc. is a commercial-stage medical device company. The company is headquartered in Irvine, California and currently employs 279 full-time employees. The company went IPO on 2025-01-30. The firm's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The firm's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The firm is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. The company is also in the early stages of developing a bihormonal configuration of the iLet.
See Also
What is Beta Bionics Inc's Change in Working Capital?
Change in Working Capital
-9m
USD
Based on the financial report for Dec 31, 2025, Beta Bionics Inc's Change in Working Capital amounts to -9m USD.
What is Beta Bionics Inc's Change in Working Capital growth rate?
Change in Working Capital CAGR 3Y
-48%
Over the last year, the Change in Working Capital growth was 26%. The average annual Change in Working Capital growth rates for Beta Bionics Inc have been -48% over the past three years .
